What changed between these versions
A substantive expansion of the prohibition against kickbacks to pharmacy benefit managers. v2 broadens the scope of prohibited compensation beyond mere referrals to include payments related to various contracting processes and introduces a rebuttable presumption for payments to brokers and consultants, requiring documentation of fair market value for bona fide services.
Overview
The bill features several significant changes concentrated within its core operative section. · v2 significantly expands the scope of prohibited activities related to pharmacy benefit manager kickbacks and adds new provisions to clarify the characterization of compensation and establish a rebuttable presumption for certain payments.
The most significant change in v2 is the expansion of prohibited compensation for pharmacy benefit management services. While v1 focused solely on "referral" payments, v2 broadens this to include payments for "recommendation, placement, retention, or renewal" of business, as well as payments related to "inclusion in, participation in, or the design of" various contracting processes like RFPs and market checks. Additionally, v2 introduces a new subclause establishing a rebuttable presumption that compensation paid to brokers or consultants by service providers is related to prohibited activities, unless fair market value for bona fide services can be demonstrated.
Major additions
This new subclause specifies that the characterization of compensation, for the purposes of the prohibition, must be based on the economic substance and practical operation of the contract or arrangement, rather than merely the label given to the compensation by the service provider.
This addition aims to prevent circumvention of the kickback prohibition through creative labeling of payments. It ensures that the intent of the law is applied based on the actual nature of the transaction, making it more difficult for entities to disguise prohibited kickbacks.
This new subclause establishes a rebuttable presumption that any compensation paid by a covered service provider to a brokerage firm, broker, consultant, advisor, or related entity is related to the prohibited activities (referral, recommendation, contracting processes). This presumption can only be overcome if the parties demonstrate through contemporaneous written documentation that such compensation reflects fair market value for bona fide services actually rendered and is not directly or indirectly related to any of the prohibited activities.
This is a significant enforcement mechanism. It shifts the burden of proof onto the service provider and related entities to justify payments, rather than requiring the covered plan or regulator to prove a kickback. This provision is likely to increase transparency and accountability in compensation arrangements between PBMs and intermediaries.
Modifications
This change has no operative impact on the substance or enforcement of the bill's provisions.
Before
The section was titled "PBM KICKBACK PROHIBITION."
After
The section is now titled "PROHIBITION ON PHARMACY BENEFIT MANAGER KICKBACKS."
This modification broadens the types of payments considered illegal kickbacks, making a wider array of compensation arrangements between PBMs and intermediaries subject to the prohibition. This will require PBMs and their partners to scrutinize more types of payments to ensure compliance, potentially leading to greater transparency and reduced costs for covered plans.
Before
Prohibited compensation paid by a service provider to an intermediary for "the referral of the covered plan's or health insurance issuer's business."
After
Prohibits compensation (direct or indirect) paid by a service provider to any individual or entity for: (aa) "the referral, recommendation, placement, retention, or renewal of, or access to, the business" of the covered plan or issuer; OR (bb) "inclusion in, participation in, or the design of" various contracting processes including RFPs, market checks, evaluations, or the volume/value/use of business.
Scope
Meaningful expansion or narrowing — Changes are concentrated within Section 2, which contains the entirety of the bill's operative text. — v2 represents a meaningful expansion of the policy direction by broadening the definition of prohibited kickbacks and introducing a significant enforcement mechanism. — The changes directly modify and expand the scope of an existing provision within the Employee Retirement Income Security Act (ERISA), specifically section 408(b)(2)(B), by adding new subclauses that define and enforce the prohibition on PBM kickbacks.
Impact analysis
Pharmacy Benefit Managers (PBMs) and Covered Service Providers
Negative (increased restrictions, compliance burden) but intended to promote fair practices.
Face a significantly broader definition of prohibited kickbacks, extending beyond simple referrals to include payments related to recommendations, retention, and involvement in various contracting processes. They also face a new rebuttable presumption for payments to intermediaries.
Brokerage firms, brokers, consultants, advisors, and related entities involved in pharmacy benefit management services
Negative (increased scrutiny, documentation burden) but intended to promote fair practices.
Compensation received from PBMs is now subject to a rebuttable presumption of being a prohibited kickback. They must now proactively demonstrate through contemporaneous written documentation that such compensation reflects fair market value for bona fide services and is unrelated to prohibited activities.
Covered Plans and Health Insurance Issuers offering health insurance coverage for covered plans
Positive (potential for cost savings, increased transparency).
Benefit from a more robust prohibition against PBM kickbacks, which could lead to greater transparency in pharmacy benefit management services and potentially lower costs for prescription drugs due to reduced hidden fees or inflated charges.